CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for TWi Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

TWi Pharmaceuticals, Inc.
4F, No.41
Lane 221, Kang Chien Road, Neihu Dist.
Phone: +886 226573350p:+886 226573350 Taipei, 114  Taiwan, Republic of China Fax: +886 226573391f:+886 226573391
This company is no longer actively traded on any major stock exchange.
Business Summary
TWi Pharmaceuticals, Inc. is engaged in the development, commissioned manufacturing and commissioned research of special pharmaceuticals. The Company focuses on the development of two categories of high barrier generic drugs: Paragraph IV of Abbreviated New Drug Applications (ANDAs) and generics with high technical barriers. The Company is involved in the commissioned manufacture of Divalproex Sodium Extended Release Tablet, which are oral tablets used as antiepileptic drug; the commissioned research and development of generic drugs to meet its customer’s specific needs, and the manufacture and sale of oral tablets and capsules used for the treatment of hypertension, depression, and gastro esophageal reflux diseases. The Company distributes its products in the United States and Taiwan.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/201912/31/2018Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
8999 Services, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Chih-MingChen 1/1/2018
Chief Operating Officer, Deputy General Manager ShelleyChiou 10/1/2018 10/1/2018
General Manager, Director NickLiu 6/8/2018 6/8/2018
9 additional Officers and Directors records available in full report.

General Information
Number of Employees: 215 (As of 9/30/2014)
Outstanding Shares: 120,368,650 (As of 6/30/2019)
Shareholders: 3,718
Stock Exchange: TPO
Fax Number: +886 226573391


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023